Chemo With or Without Veliparib Active in BRCA/PALB2+ Pancreatic Cancer
The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma (PDAC) and a germline BRCA/PALB2 mutation.
In a randomized, multinational phase II trial, both combinations exceeded the prespecified threshold for response rate, with higher rates of grade 3/4 hematologic toxicity observed with the triplet compared with the doublet, Eileen M. O’Reilly, MD, said at the 2020 Gastrointestinal Cancers Symposium. Read more . . .
